Contents

➔ Company Overview
➔ Our Mission
➔ Opportunity Summary
➔ External Highlights
➔ Success Stories
➔ Press Releases
➔ Financials
Company Overview

Company

GI Dynamics is the developer of EndoBarrier, the first endoscopically-delivered device approved for the treatment of type 2 diabetes and obesity. EndoBarrier is not approved for sale in the United States and is limited by federal law to investigational use only in the United States. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts. For more information, please visit www.gidynamics.com.

Product

The EndoBarrier is a thin flexible sleeve that is placed inside your intestine (below your stomach) creating a physical barrier between the intestinal wall and the food you eat. The liner is flexible and moves with your body after placement. There are no incisions needed in the placement or removal of the EndoBarrier.

Click on an image below to view the mechanism of action.

Product Benefits

➔ Reduces HbA1c levels
➔ Reduces weight
➔ Reduction in associated health problems due to high blood sugar, obesity, and insulin use.
➔ Reversible 12-month implant
➔ Improves long-term health and cardiac risk
GI Dynamics is led by a team of business, technology experts and medical device industry veterans with a successful track record of leading turnarounds and commercializing important, novel healthcare technologies.

Scott Schorer  
President & Chief Executive Officer  
Scott brings over 20 years of executive experience in the medical device industry, having both founded and helmed numerous companies in the healthcare space.

Brian Callahan  
Chief Compliance Officer, Executive Vice President Clinical, Regulatory and Quality  
Brian is an accomplished senior compliance executive with more than 25 years of experience in the medical device, pharmaceutical and biologics industries.

Jim Murphy  
Chief Financial Officer  
Jim Murphy is an accomplished senior finance executive with more than 30 years of experience in high-growth domestic and international environments and extensive experience in the life science sector.
GI Dynamics is privileged to have as our scientific advisors a prestigious, multidisciplinary group of leaders dedicated to advancing research for the treatment of type 2 diabetes, obesity and other metabolic disorders.

**Endocrinology**

**David E. Cummings, MD**  
*Endocrinologist, Washington, DC, U.S.A.*

“I’m very excited to join the team at GI Dynamics and help move EndoBarrier forward,” said Cummings. “This novel device has strong potential to recapitulate some of the magic of bariatric/metabolic operations for type 2 diabetes and obesity without the invasiveness of surgery.”

**Carel le Roux, MD, PhD**  
*Endocrinologist, Dublin, Ireland*

“Type 2 diabetes remains one of the most challenging chronic diseases people struggle with. Novel and scalable treatments that can have a positive impact on people’s lives are urgently needed,” said Le Roux. “EndoBarrier has broken the mold of how we used to think about novel treatments for diabetes.”

**Gastroenterology**

**Gerald Holtmann, MD**  
*Gastroenterologist, Brisbane, Australia*

“With my current research focused on the role of gut microbiome and brain—gut interactions, I’m excited to contribute to the GI Dynamics SAB,” said Dr. Holtmann. “Understanding the role of EndoBarrier should produce interesting research that will hopefully help patients.”

**Manoel Galvao Neto, MD**  
*Gastroenterologist, Sao Paulo, Brazil*

“Since my first-in-human EndoBarrier implant in 2005, I have seen the health benefit it offers to patients in need of an alternative treatment,” said Galvao. “I truly believe EndoBarrier fills the existing type 2 diabetes treatment gap.”

**Thomas Rösch, MD**  
*Gastroenterologist, Hamburg, Germany*

“The innovation of endoscopic procedures continues to advance treatments in many disease states,” said Dr. Rösch. “By being part of the GI Dynamics Scientific Advisory Board, I will have the opportunity to help understand these innovations and hopefully advance treatment for the many people diagnosed with obesity and type 2 diabetes.”
Gastroenterology (continued)

Christopher C Thompson, MD FACG AGAF FASGE
Gastroenterologist, Boston, MA, U.S.A.

“EndoBarrier is an exciting and novel technology that fills a rapidly expanding treatment gap in the management of type 2 diabetes and obesity. The GI Dynamics team has pioneered the advancement of our understanding of disease and treatment mechanisms over the past decade, and this device holds tremendous promise,” said Dr. Thompson. “I am thrilled to be joining such an accomplished group of clinicians and look forward to collaborating with them.”

Metabolic Surgery

Ricardo Cohen, MD
Bariatric / Metabolic Surgeon, Sao Paulo, Brazil

“GI Dynamics with EndoBarrier has produced an excellent adjuvant tool to achieve diabetes control,” said Dr. Cohen. “I look forward to helping GI Dynamics continue to develop EndoBarrier to provide a safe and effective device in a treatment area that is growing rapidly.”

Jan Willem Greve, MD, PhD
Bariatric / Metabolic Surgeon, Heerlen, Netherlands

“Obesity and its co-morbidities are an immense challenge for modern health care,” said Greve. “Bariatric or metabolic surgery is a proven tool to treat morbidly obese patients with type 2 diabetes. However, the majority of these patients may have a BMI that is too low or have serious contraindications that preclude them from being candidates for such an invasive surgical procedure. As a bariatric / metabolic surgeon, I believe EndoBarrier is a powerful addition to our treatment armamentarium.”

Francesco Rubino, MD
Bariatric / Metabolic Surgeon, London, UK

“The potential impact of EndoBarrier for the treatment of both type 2 diabetes and obesity in less obese patients is truly exciting. I look forward to working with the GI Dynamics SAB to further study EndoBarrier and its many benefits for patients.”

Philip Schauer, MD
Bariatric / Metabolic Surgeon, Cleveland, OH, U.S.A.

“EndoBarrier is bridging the gap in care for patients struggling to control their HbA1c levels with ever-increasing doses of insulin but do not meet the criteria for gastric bypass surgery. I am excited to help advance the tools that will provide a powerful treatment option for this patient population.”

Check out full bios for the Scientific Advisory Board here
Our Mission: to alleviate the symptoms of type 2 diabetes for patients worldwide with a minimally invasive and reversible implant.
Opportunity Summary

➔ Unique implant for treating the large unmet need of type 2 diabetes and obesity

➔ Significant efficacy in glucose control, weight loss and other risk factors

➔ Less invasive therapy with advantageous cost-benefit profile

➔ Substantial commercial & clinical experience > 3,700 shipped

➔ New team rebuilding confidence

Recently Published Worldwide Clinical Data

ABCD EndoBarrier®/Victoza®
- UK: Ryter
- HbA1c, Weight: 72

EndoMeta
- France: Pattou
- HbA1c, weight, Metabolic: 90

CV Inflammation Biomarkers
- Germany: Seufert
- Biomarker Measures: 45

ABCD T2D + Obesity
- UK: Teare
- HbA1c, Weight: 80

ADHD: T2D + Obesity
- USA: Study Team
- HbA1c, Weight: 201/325

ABCD EndoBarrier® NAFLD
- UK: Hayee
- NFS, HbA1c: 8

EndoBarrier NAFLD
- Germany: Lautner
- NFS: 45

Adolescent Obesity
- Slovenia: Battelino
- Markers: 20

ASCH, Fat Absorption
- Australia: Hoffmann
- Weight, NFS: 40

Recently Published Worldwide Clinical Data

Germany Registry
- 305
- Safety & Efficacy
- Q3 2015
- Releasing Data '16

ABCD Global Registry
- >250
- EndoBarrier Safety & Efficacy
- Q2 2016
- Complete
- Initiating site recruitment and data entry

10-3 Registry
- Safety & Efficacy
- 240 Entered
- Completed

Media Kit 2017 | GI Dynamics®, Inc.
External Highlights

**Accolades**

*EndoBarrier Endorsed by 3 German Societies*
Position Paper of Scientific Societies for Recommended Usage of Endoscopic Biliodigestive Diversion in Germany

- German Diabetes Association ("DDG")
- German Society for General and Visceral Surgery ("DGAV")
- German Society for Digestive and Metabolic Diseases ("DGVS")

**EndoBarrier Videos and Case Studies**

**BBC News item**
EndoBarrier treatment for diabetes & obesity following 1 year results of ABCD study

**Product Overview**
Pioneering treatment for diabetes & obesity

**ABCD EndoBarrier Study**
1-year results, including 10-year CV
Risk assessment - Dr Bob Ryder, 2016

**Maintenance of Efficacy after EndoBarrier**
UK First NHS EndoBarrier Service - Dr. Bob Ryder June 2017

**EndoBarrier - Philadelphia CBS Channel 3**
Success Stories

Discover more about our patient’s success and view videos at: success.gidynamics.com

### Overall Results: HbA1c: 2.5% | Weight: 18.7kg | BMI: 7.2kg/m²

**Placement: 0 mos**

**EndoBarrier Removal: 12 mos**

**Post EndoBarrier: 24 Mos**

<table>
<thead>
<tr>
<th>HbA1c</th>
<th>Weight</th>
<th>BMI</th>
<th>Insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>70 mmol/mol (8.6%)</td>
<td>82.9 kg</td>
<td>33.6 kg/m²</td>
<td>0 units</td>
</tr>
<tr>
<td>51 mmol/mol (6.8%)</td>
<td>62.2 kg</td>
<td>24.7 kg/m²</td>
<td>0 units</td>
</tr>
<tr>
<td>43 mmol/mol (6.1%)</td>
<td>64.2 kg</td>
<td>26.4 kg/m²</td>
<td>0 units</td>
</tr>
</tbody>
</table>

**Net Results**

- 1.8% HbA1c
- 20.7 kg (45.6 lbs)
- Normal BMI

**Net Results**

- 0.7% HbA1c
- 2 kg (4.4 lbs)
- Normal BMI

**Net Results**

- 0.1% HbA1c
- 4.2 kg (9.2 lbs)
- 1.2 BMI

---

### Overall Results: HbA1c: 2.6% | Weight: 24.2kg | BMI: 8kg/m²

**Placement: 0 mos**

**EndoBarrier Removal: 12 mos**

**Post EndoBarrier: 24 Mos**

<table>
<thead>
<tr>
<th>HbA1c</th>
<th>Weight</th>
<th>BMI</th>
<th>Insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>76 mmol/mol (9.7%)</td>
<td>16.6 kg</td>
<td>38.0 kg/m²</td>
<td>42 units</td>
</tr>
<tr>
<td>40 mmol/mol (6.6%)</td>
<td>88.9 kg</td>
<td>28.8 kg/m²</td>
<td>0 units</td>
</tr>
<tr>
<td>47 mmol/mol (6.5%)</td>
<td>92.2 kg</td>
<td>30.0 kg/m²</td>
<td>0 units</td>
</tr>
</tbody>
</table>

**Net Results**

- 2.5% HbA1c
- 28.4 kg (62.6 lbs)
- 9.2 BMI

**Net Results**

- 0.7% HbA1c
- 4.2 kg (9.2 lbs)
- 1.2 BMI

**Net Results**

- 1.3% HbA1c
- 0.6 kg (1.3 lbs)
- Normal BMI

---

### Overall Results: HbA1c: 0.3% | Weight: 20.4kg | BMI: 7.9kg/m²

**Placement: 0 mos**

**EndoBarrier Removal: 12 mos**

**Post EndoBarrier: 24 Mos**

<table>
<thead>
<tr>
<th>HbA1c</th>
<th>Weight</th>
<th>BMI</th>
<th>Insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>61 mmol/mol (7.7%)</td>
<td>86.6 kg</td>
<td>35.3 kg/m²</td>
<td>0 units</td>
</tr>
<tr>
<td>43 mmol/mol (6.1%)</td>
<td>65.6 kg</td>
<td>26.2 kg/m²</td>
<td>0 units</td>
</tr>
<tr>
<td>57 mmol/mol (7.4%)</td>
<td>66.2 kg</td>
<td>27.2 kg/m²</td>
<td>0 units</td>
</tr>
</tbody>
</table>

**Net Results**

- 1.6% HbA1c
- 21.2 kg (46.2 lbs)
- Normal BMI

**Net Results**

- 1.3% HbA1c
- 0.6 kg (1.3 lbs)
- Normal BMI

**Net Results**

- 0.3% HbA1c
- 20.4 kg (45.6 lbs)
- 7.9 BMI

---

Patient supplied data
Success Stories

Discover more about our patient success and view videos at: success.gidynamics.com

Patient supplied data
24 September 2017 | **IK+EM Study Released at EASD Shows Similar Outcomes Between Gastric Plication and EndoBarrier**

LISBON, PORTUGAL — 25 September 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces that new data has been released from the Institute for Clinical and Experimental Medications (“IK+EM”) on the comparison of 40 patients who underwent either gastric plication or EndoBarrier treatment or were control patients. The IK+EM released the data at the 53rd Annual Meeting of the European Association for the Study of Diabetes (“EASD”). [Link](#)

12 June 2017 | **First Data Derived from ABCD Worldwide EndoBarrier Registry Presented at ADA Shows Sustained Metabolic Improvements in Patients with Obesity and Type 2 Diabetes at Six Months Post-explant**

GI Dynamics®, Inc., (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe for patients with type 2 diabetes and obesity, today announced data from a UK National Health Service (NHS) EndoBarrier Registry presented at the American Diabetes Association’s 77th Scientific Sessions demonstrated that metabolic improvements made by patients while implanted with EndoBarrier were sustained six months after EndoBarrier was explanted. [Link](#)

22 May 2017 | **Meta-Analysis Show EndoBarrier Improves Glycemic Control, Induces Weight Loss in Patients with Type 2 Diabetes and Obesity**

GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, today announced data from an investigator-initiated meta-analysis of 14 studies showing EndoBarrier improves glycemic control in a clinically impactful manner in patients with type 2 diabetes and obesity. According to data presented at the Digestive Disease Week (DDW) meeting in Chicago, EndoBarrier induces significant weight loss and positively affects certain digestive hormones. [Link](#)

15 February 2017 | **EndoBarrier® Study in Morbidly Obese Adolescents Completes Enrollment**

GI Dynamics, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier in Europe for patients with type 2 diabetes and obesity, today announced that enrollment is complete in the first clinical trial evaluating EndoBarrier in adolescents. The study was conducted at the University Children’s Hospital (UCH) in Ljubljana, Slovenia. [Link](#)
22 August 2017 | GI Dynamics Appoints Juliet Thompson to Company’s Board of Directors

BOSTON and SYDNEY— 23 August 2017— GI Dynamics® Inc. (ASX:GID), a medical device company that commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity announces the appointment of medical and financial markets veteran Juliet Thompson to the company’s board of directors, effective immediately. Link

13 August 2017 | GI Dynamics Welcomes New Members to Its Scientific Advisory Board

BOSTON and SYDNEY — 14 August 2017 — GI Dynamics® Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, welcomed new members to the GI Dynamics Scientific Advisory Board (SAB), bringing together distinguished physicians and scientists specializing in endocrinology, gastroenterology and bariatric/metabolic surgery. Gerald Holtmann, MD, and Thomas Rösch, MD, have joined the GI Dynamics SAB. Link

9 August 2017 | GI Dynamics to Provide Shareholder Update on 2017 Second Quarter Results

BOSTON and SYDNEY – 10 August 2017 – GI Dynamics® Inc. (ASX: GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces it will update investors on 2017 second quarter results as reported on Form 10Q for the period ended June 30, 2017. Link

25 July 2017 | GI Dynamics Selects Proven Process Medical Devices as Contract Manufacturer

BOSTON and SYDNEY – 26 July 2017 – GI Dynamics® Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, today announced the selection of Proven Process Medical Devices, Inc. (PPMD) as its contract manufacturing partner. Link

20 July 2017 | GI Dynamics Selects Proven Process Medical Devices as Contract Manufacturer

BOSTON and SYDNEY – 26 July 2017 – GI Dynamics® Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, today announced the selection of Proven Process Medical Devices, Inc. (PPMD) as its contract manufacturing partner. Link
Financials

Financial Materials
➔ Q2 2017 Form 10-K
➔ Q3 2016 Appendix 4C
➔ Q3 2016 Appendix 10Q
➔ Q2 2016 Appendix 10Q
➔ Q1 2016 Appendix 4C
➔ Q1 2016 Appendix 10Q
➔ 2015 Form 10-K

Financial PR & UK Investor Relations
Walbrook PR Ltd
4 Lombard Street
London
EC3V 9HD
Tel: + 44 (0)20 7933 8780
gid@walbrookpr.com

United States Investor Relations
Janell Shields
Tel: +1-781-357-3280
investor@gidynamics.com

Share Registry
Link Market Services Limited
General Shareholder Enquiries:
Phone: 1300 554 474 (toll free) or +61 2 8280 7111
registrars@linkmarketservices.com.au
Fax: +61 2 9287 0303

Online investor log-in
Locked Bag A14
Sydney South NSW 1235
Australia

Contact Information
355 Congress Street,
4th Floor
Boston, MA
United States
Tel: +1-781-357-3300
Fax: +1-781-357-3301
Email: info@gidynamics.com